Liver News and Research

RSS

Missing link between fructose, insulin resistance found

A new study in mice sheds light on the insulin resistance that can come from diets loaded with high-fructose corn syrup, a sweetener found in most sodas and many other processed foods.

2 Apr 2009

Is telmisartan effective in treating non-alcoholic steatohepatitis?

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are well-recognized causes of progressive liver disease leading to cirrhosis and hepatocellular carcinoma.

2 Apr 2009

Drugs that act on 'fasting signal' may curb insulin resistance in obese

A report in the March issue of Cell Metabolism , a Cell Press publication, has found that a signal known to play a role during fasting also switches on early in the fat tissue of obese mice as they progress toward type 2 diabetes.

2 Apr 2009

Colonoscopy versus virtual colonoscopy

Today, patients have a wide selection of colorectal cancer screening exams from which to choose, unlike with other types of cancers.

2 Apr 2009

The immune system's role in hepatitis C recurrence after liver transplantation

A new study pinpoints certain aspects of the immune system that may play a role in the recurrence and progression of hepatitis C virus (HCV) after liver transplantation.

1 Apr 2009

Discovery of new fat-fighting pathway

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a process that controls the amount of fat that cells store for use as a back-up energy source.

1 Apr 2009

Research looks at the elimination of hepatitis B and C

Two new studies in the April issue of Hepatology explore the ways that hepatitis B virus (HBV) and hepatitis C virus (HCV) can be cleared from patients' bodies.

1 Apr 2009

Sorafenib may help patients suffering from advanced portal hypertension

In a new study, a therapeutic agent called sorafenib dramatically improved the condition of rats with portal hypertension.

1 Apr 2009

ImQuest presents data on the anti-hepatitis B virus activity of Pyrimidinediones

ImQuest Life Sciences today presented important new results on the continued development of the pyrimidinedione small molecules as antiviral agents at the 13th International Symposium on Viral Hepatitis and Liver Disease meeting held last week in Washington D.C.

31 Mar 2009

Amniotic fluid may be a new source of stem cells

For the first time, scientists have shown that amniotic fluid (the protective liquid surrounding an embryo) may be a potential new source of stem cells for therapeutic applications. The study was prepublished online on February 12, 2009, in Blood, the official journal of the American Society of Hematology.

31 Mar 2009

Research helps explain how chronic liver damage can eventually lead to cancer

Liver damage can be triggered by various insults, including hepatitis infection or alcohol-induced cirrhosis.

30 Mar 2009

In lab supplements of lipoic acid lower triglyceride levels

Studies done with laboratory rats suggest that supplementation of their diet with lipoic acid had a significant effect in lowering triglycerides, which along with cholesterol levels and blood pressure are one of the key risk factors in cardiovascular disease.

30 Mar 2009

Melatonin may be served as a potential anti-fibrotic drug

In China, the incidence of liver cirrhosis is still high. Liver cirrhosis results from fibrosis. If treated properly at fibrosis stage, cirrhosis can be prevented.

30 Mar 2009

Potential therapeutic strategy for fulminant hepatic failure

Fulminant hepatic failure is a serious clinical disease and may threaten the life of patients. However, because of the damage of mass liver cells, the organ function is often irreversible due to the liver cell degeneration, swelling, or apoptosis.

30 Mar 2009

New molecular marker of gastric cancer

Gastric cancer (GC) is one of the most common malignancies in the world with a high incidence and death rate.

30 Mar 2009

NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management

Data from a new study showed that Abbott's TRILIPIX (fenofibric acid) delayed-release capsules in combination with rosuvastatin calcium met all of the study's primary endpoints.

29 Mar 2009